Global /Ireland /Healthcare /Drug Manufacturers - Specialty & Generic /AVDL

Avadel Pharmaceuticals plc

AVDL

• NASDAQ: AVDL • Delayed

21.64USD 0%

As of 9 June 2026, Avadel Pharmaceuticals plc has a market cap of $2.12B USD, ranking #6746 globally and #27 in Ireland. It ranks #541 in the Healthcare sector, and #19 in the Drug Manufacturers - Specialty & Generic industry.

Global Rank

6746

Country Rank

Sector Rank

541

Industry Rank

Key Stats

Market Cap

$2.12BUSD

Enterprise Value

$2.07BUSD

Revenue (TTM)

$248.52MUSD

EBITDA (TTM)

$2.7MUSD

Net Income (TTM)

-$278.0KUSD

EBITDA Margin

1.1%

Profit Margin

-0.1%

Forward PE

33.2

PS Ratio

8.4

PB Ratio

21.4

EV/EBITDA

766.9

Company Profile

Country (HQ)

Ireland

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Gregory Divis open_in_new

Employees

188

Founded

2015

IPO

07 Jun 1996

Website

avadel.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	0.3%	0.7%	16%	70%	0.4%	138%	187%	134%

News

AVDL Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	AVDL Avadel Pharmaceuticals PLC ISIN: IE00BDGMC594 Shares Out.: Shares Outstanding: 97.818M¹ Shares Float: 90.948M² TV: TradingView: NASDAQ: AVDL SA: Stock Analysis: NASDAQ: AVDL YF: Yahoo Finance: AVDL GF: Google Finance: NASDAQ: AVDL NQ: NASDAQ: AVDL BA: Barron's: AVDL MS: Morningstar: XNAS: AVDL	21.64 USD	TV: TradingView: NASDAQ: AVDL SA: Stock Analysis: NASDAQ: AVDL YF: Yahoo Finance: AVDL GF: Google Finance: NASDAQ: AVDL NQ: NASDAQ: AVDL BA: Barron's: AVDL MS: Morningstar: XNAS: AVDL

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (Global)

Name	Market Cap (USD) diff.	PE	Country
Teva Pharmaceutical Industries Ltd. TLV: TEVA	$37.19B 108.92B ILS 2K%	24.2	Israel
Revolution Medicines, Inc. NASDAQ: RVMD	$29.56B 1K%	-	United States
Zhejiang NHU Company Ltd. SHE: 002001	$15.86B 107.34B CNY 647%	16.0	China
Cipla Ltd. NSE: CIPLA	$11.13B 1.06T INR 424%	23.4	India
Lupin Ltd. NSE: LUPIN	$11.02B 1.05T INR 419%	22.7	India
Haisco Pharmaceutical Group Co., Ltd. SHE: 002653	$9.1B 61.6B CNY 329%	80.6	China

chevron_leftBack